Table 2. Data extracted from the included studies in the meta-analysis for an association between toxoplasmosis and RA.
| No | Reference | N | Case: RA+ (n) | Control: RA- (n) | RA+ & T+ (n, %) | RA- & T+ (n, %) | OR (95% CI) | P-value |
|---|---|---|---|---|---|---|---|---|
| 1 | Shapira Y [14] (Latin America) | 292 | 152 | 140 | 55 (36.18%) | 50 (35.71%) | 1.02 (0.62–1.70) | NS |
| 2 | Shapira Y [14] (Europe) | 332 | 35 | 297 | 27 (77.14%) | 77 (25.93%) | 9.64 (4.02–25.44) | < 0.0001 |
| 3 | Kuba RH [27] (Treated) | 344 | 294 | 50 | 98 (33.33%) | 6 (12%) | 3.67 (1.48–10.86) | < 0.05 |
| 4 | Kuba RH [27] (Untreated) | 100 | 50 | 50 | 18 (36%) | 6 (12%) | 4.13 (1.36–13.97) | < 0.05 |
| 5 | Al kalaby RF [22] | 69 | 44 | 25 | 23 (52.27%) | 5 (20%) | 4.38 (1.26–17.31) | 0.01 |
| 6 | El-Sayed NM [25] | 150 | 100 | 50 | 54 (54%) | 16 (32%) | 2.49 (1.16–5.47) | S |
| 7 | Flegr J [26] | 1320 | 301 | 1019 | 6 (46.15%) | 295 (22.57%) | 2.94 (0.81–10.30) | 0.012 |
| 8 | El- Henawy AA [24] | 120 | 60 | 60 | 46 (76.67%) | 29 (48.3%) | 3.51 (1.50–8.35) | < 0.001 |
| 9 | Tian A-L [28] | 1058 | 157 | 901 | 59 (24.79%) | 98 (11.59%) | 2.43 (1.66–3.53) | < 0.001 |
| 10 | Al- Oqaily MA [23] | 308 | 258 | 50 | 95 (36.82) | 0 (0%) | 58.99 (7.35-infinity) | < 0.0001 |
N and n: Number, CI: Confidence interval; RA+: People with rheumatoid arthritis; RA-: People without rheumatoid arthritis; RA+ & T+: People with rheumatoid arthritis and Toxoplasma positive; RA- & T+: People without rheumatoid arthritis and Toxoplasma positive; OR: Odds ratio; NS: Not significant; S: Significant